-
1
-
-
79251470391
-
Projections of the cost of cancer care in the United States: 2010-2020
-
Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 117-128
-
-
Mariotto, A.B.1
Yabroff, K.R.2
Shao, Y.3
-
2
-
-
33847676571
-
-
Centers for Medicare and Medicaid Services: National health expenditures projections 2011-2021. http:// www.cms.gov/Research-Statistics-data-and-Systems/ Statistics-Trends-and-Reports/NationalHealth ExpendData/Downloads/Proj2011PDF. pdf
-
National Health Expenditures Projections
-
-
-
3
-
-
84863195517
-
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology
-
Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715- 1724, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 1715-1724
-
-
Schnipper, L.E.1
Smith, T.J.2
Raghavan, D.3
-
4
-
-
84864976091
-
When the cost curve bent: Pre-recession moderation in health care spending
-
Roehrig C, Turner A, Hughes-Cromwick P, et al: When the cost curve bent: Pre-recession moderation in health care spending. N Engl J Med 367: 590-593, 2012
-
(2012)
N Engl J Med
, vol.367
, pp. 590-593
-
-
Roehrig, C.1
Turner, A.2
Hughes-Cromwick, P.3
-
6
-
-
80755126820
-
Antiemetics: American Society of Clinical Oncology clinical practice guideline update
-
Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 4189-4198
-
-
Basch, E.1
Prestrud, A.A.2
Hesketh, P.J.3
-
7
-
-
58749100277
-
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial
-
Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
-
(2009)
Lancet Oncol
, vol.10
, pp. 115-124
-
-
Saito, M.1
Aogi, K.2
Sekine, I.3
-
8
-
-
77953349334
-
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
-
Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
-
(2010)
Ann Oncol
, vol.21
, pp. 1083-1088
-
-
Aapro, M.1
Fabi, A.2
Nolè, F.3
-
9
-
-
57849152399
-
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
-
Yu Z, Liu W, Wang L, et al: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99-102, 2009
-
(2009)
Support Care Cancer
, vol.17
, pp. 99-102
-
-
Yu, Z.1
Liu, W.2
Wang, L.3
-
10
-
-
84862544485
-
1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1)
-
Cardoso F, Costa A, Norton L, et al: 1st International Consensus Guidelines for Advanced Breast Cancer (ABC 1). Breast 21:242-252, 2012
-
(2012)
Breast
, vol.21
, pp. 242-252
-
-
Cardoso, F.1
Costa, A.2
Norton, L.3
-
11
-
-
70349260426
-
Single agent versus combination chemotherapy for metastatic breast cancer
-
Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372, 2009
-
(2009)
Cochrane Database Syst Rev
, vol.15
-
-
Carrick, S.1
Parker, S.2
Thornton, C.E.3
-
13
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
14
-
-
84876970810
-
Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
-
Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
-
(2013)
Lancet Oncol
, vol.14
, pp. 461-471
-
-
Swain, S.M.1
Kim, S.B.2
Cortés, J.3
-
15
-
-
0037102121
-
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
-
Howell A, Robertson JF, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 3396-3403
-
-
Howell, A.1
Robertson, J.F.2
Quaresma Albano, J.3
-
16
-
-
79951956249
-
Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline
-
Lutz S, Berk L, Chang E, et al: Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965-976, 2011
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.79
, pp. 965-976
-
-
Lutz, S.1
Berk, L.2
Chang, E.3
-
17
-
-
0242302433
-
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: The PLUS study
-
Verboom P, van Tinterer H, Hoekstra OS, et al: Cost-effectiveness of FDG-PET in staging nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 30:1444-1449, 2003 (Pubitemid 37356109)
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.11
, pp. 1444-1449
-
-
Verboom, P.1
Van Tinteren, H.2
Hoekstra, O.S.3
Smit, E.F.4
Van Den Bergh, J.H.A.M.5
Schreurs, A.J.M.6
Stallaert, R.A.L.M.7
Van Velthoven, P.C.M.8
Comans, E.F.I.9
Diepenhorst, F.W.10
Van Mourik, J.C.11
Postmus, P.E.12
Boers, M.13
Grijseels, E.W.M.14
Teule, G.J.J.15
Uyl-de Groot, C.A.16
-
18
-
-
0031801682
-
Analytical decision model for the cost-effective management of solitary pulmonary nodules
-
Gambhir SS, Shepherd JE, Shah BD, et al: Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 16:2113-2125, 1998 (Pubitemid 28265048)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.6
, pp. 2113-2125
-
-
Gambhir, S.S.1
Shepherd, J.E.2
Shah, B.D.3
Hart, E.4
Hoh, C.K.5
Valk, P.E.6
Emi, T.7
Phelps, M.E.8
-
20
-
-
84905915734
-
-
Cancer Care Ontario
-
Cancer Care Ontario: PET imaging in Ontario. http://www.cancercare.on.ca/ ocs/clinicalprogs/imaging/ pet
-
PET Imaging in Ontario
-
-
-
21
-
-
77954320936
-
Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and followup
-
Labianca R, Norlinger B Becotta GD, et al: Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and followup. Ann Oncol 21:v70-v77, 2010 (suppl 5)
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
Labianca, R.1
Norlinger, B.2
Becotta, G.D.3
-
22
-
-
84881115822
-
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
-
Cheah CY, Hofman MS, Dickinson M, et al: Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109:312-317, 2013
-
(2013)
Br J Cancer
, vol.109
, pp. 312-317
-
-
Cheah, C.Y.1
Hofman, M.S.2
Dickinson, M.3
-
23
-
-
34347253223
-
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
-
DOI 10.3324/haematol.10798
-
Zinzani P, Tani M, Trisolini R, et al: Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92:771-777, 2007 (Pubitemid 350155302)
-
(2007)
Haematologica
, vol.92
, Issue.6
, pp. 771-777
-
-
Zinzani, P.L.1
Tani, M.2
Trisolini, R.3
Fanti, S.4
Stefoni, V.5
Alifano, M.6
Castellucci, P.7
Musuraca, G.8
Dalpiaz, G.9
Alinari, L.10
Marchi, E.11
Fina, M.12
Pellegrini, C.13
Farsad, M.14
Cancellieri, A.15
Busca, A.16
Canini, R.17
Pileri, S.18
Baccarani, M.19
Boaron, M.20
more..
-
24
-
-
79551559469
-
Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer
-
Evangelista L, Baretta, Vinante L, et al: Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 38:293-301, 2011
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 293-301
-
-
Evangelista, L.1
Baretta2
Vinante, L.3
-
25
-
-
40349096407
-
18FDG-PET in the follow-up of patients with colorectal cancer
-
DOI 10.1038/sj.bjc.6604263, PII 6604263
-
Sobhani I, Tiret E, Lebtahi R, et al: Early detection of recurrence by 18 FDG-PET/CT in the follow-up of patients with colorectal cancer. Br J Cancer 98:875-880, 2008 (Pubitemid 351341613)
-
(2008)
British Journal of Cancer
, vol.98
, Issue.5
, pp. 875-880
-
-
Sobhani, I.1
Tiret, E.2
Lebtahi, R.3
Aparicio, T.4
Itti, E.5
Montravers, F.6
Vaylet, C.7
Rougier, P.8
Andre, T.9
Gornet, J.M.10
Cherqui, D.11
Delbaldo, C.12
Panis, Y.13
Talbot, J.N.14
Meignan, M.15
Le Guludec, D.16
-
26
-
-
84890917324
-
Utility of post-therapy surveillance scans in DCBCL
-
abstr 8504
-
Thompson CA, Maurer MJ, Ghesquieres H, et al: Utility of post-therapy surveillance scans in DCBCL. J Clin Oncol 31:519s, 2013 (suppl; abstr 8504)
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Thompson, C.A.1
Maurer, M.J.2
Ghesquieres, H.3
-
27
-
-
84892978390
-
Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
-
abstr 8505
-
Pingali SR, Sewell S, Havlat L, et al: Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 31:519s, 2013 (suppl; abstr 8505)
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Pingali, S.R.1
Sewell, S.2
Havlat, L.3
-
28
-
-
84872945000
-
PSA: Please stop agonizing (over prostate-specific antigen interpretation)
-
Raghavan D: PSA: Please stop agonizing (over prostate-specific antigen interpretation). Mayo Clin Proc 88:1-3, 2013
-
(2013)
Mayo Clin Proc
, vol.88
, pp. 1-3
-
-
Raghavan, D.1
-
29
-
-
0019442199
-
Use of human prostate-specific antigen in monitoring prostate cancer
-
Kuriyama M, Wang MC, Lee CI, et al: Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874-3876, 1981 (Pubitemid 11011166)
-
(1981)
Cancer Research
, vol.41
, Issue.10
, pp. 3874-3876
-
-
Kuriyama, M.1
Wang, M.C.2
Lee, C.3
-
30
-
-
82255162851
-
Baseline prostate-specific antigen testing at a young age
-
Loeb S, Carter HB, Catalona WJ, et al: Baseline prostate-specific antigen testing at a young age. Eur Urol 61:1-7, 2012
-
(2012)
Eur Urol
, vol.61
, pp. 1-7
-
-
Loeb, S.1
Carter, H.B.2
Catalona, W.J.3
-
31
-
-
63249118690
-
Screening and prostate-cancer mortality in a randomized European study
-
Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320- 1328, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 1320-1328
-
-
Schröder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
32
-
-
84858212484
-
Prostate-cancer mortality at 11 years of follow-up
-
Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
-
(2012)
N Engl J Med
, vol.366
, pp. 981-990
-
-
Schröder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
33
-
-
77955279420
-
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
-
Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
-
(2010)
Lancet Oncol
, vol.11
, pp. 725-732
-
-
Hugosson, J.1
Carlsson, S.2
Aus, G.3
-
34
-
-
63249122661
-
Mortality results from a randomized prostatecancer screening trial
-
Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostatecancer screening trial. N Engl J Med 360:1310-1319, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 1310-1319
-
-
Andriole, G.L.1
Crawford, E.D.2
Grubb III, R.L.3
-
37
-
-
84878101564
-
Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians
-
Qaseem A, Barry MJ, Denberg TD, et al: Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 158:761-769, 2013
-
(2013)
Ann Intern Med
, vol.158
, pp. 761-769
-
-
Qaseem, A.1
Barry, M.J.2
Denberg, T.D.3
-
38
-
-
84880005911
-
Early detection of prostate cancer: AUA Guideline
-
Carter HB, Albertson PC, Barry MJ, et al: Early detection of prostate cancer: AUA Guideline. J Urol 190:419-426, 2013
-
(2013)
J Urol
, vol.190
, pp. 419-426
-
-
Carter, H.B.1
Albertson, P.C.2
Barry, M.J.3
-
39
-
-
84865213012
-
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion
-
Basch E, Oliver TK, Vickers A, et al: Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 30:3020-3025, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 3020-3025
-
-
Basch, E.1
Oliver, T.K.2
Vickers, A.3
-
40
-
-
0021811764
-
Structural organization of the bcr gene and its role in the Ph' translocation
-
DOI 10.1038/315758a0
-
Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-761, 1985 (Pubitemid 15022931)
-
(1985)
Nature
, vol.315
, Issue.6022
, pp. 758-761
-
-
Heisterkamp, N.1
Stam, K.2
Groffen, J.3
-
41
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker B, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
42
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
-
43
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 3327-3334
-
-
Sequist, L.V.1
Yang, J.C.2
Yamamoto, N.3
-
44
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
45
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694- 1703, 2012
-
(2012)
N Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
-
46
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa040938
-
Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lunch cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
47
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
DOI 10.1056/NEJMoa050753
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Pereira, J.R.2
Ciuleanu, T.3
Eng, H.T.4
Hirsh, V.5
Thongprasert, S.6
Campos, D.7
Maoleekoonpiroj, S.8
Smylie, M.9
Martins, R.10
Van Kooten, M.11
Dediu, M.12
Findlay, B.13
Tu, D.14
Johnston, D.15
Bezjak, A.16
Clark, G.17
Santabarbara, P.18
Seymour, L.19
-
48
-
-
79957492069
-
American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
-
Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2121-2127
-
-
Keedy, V.L.1
Temin, S.2
Somerfield, M.R.3
-
49
-
-
36148941301
-
Cetuximab for the treatment of colorectal cancer
-
DOI 10.1056/NEJMoa071834
-
Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.20
, pp. 2040-2048
-
-
Jonker, D.J.1
O'Callaghan, C.J.2
Karapetis, C.S.3
Zalcberg, J.R.4
Tu, D.5
Au, H.-J.6
Berry, S.R.7
Krahn, M.8
Price, T.9
Simes, R.J.10
Tebbutt, N.C.11
Van Hazel, G.12
Wierzbicki, R.13
Langer, C.14
Moore, M.J.15
-
50
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
-
DOI 10.1200/JCO.2006.08.1620
-
Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007 (Pubitemid 46797944)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.13
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.-L.7
Van Laethem, J.-L.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.G.12
-
51
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757- 1765, 2008
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
52
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
Allegra C, Jessup J, Somerfield M, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 2091-2096
-
-
Allegra, C.1
Jessup, J.2
Somerfield, M.3
-
53
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
54
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
55
-
-
68049124818
-
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer
-
Jimeno A, Messersmith WA, Hirsch FR, et al: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J 15:110- 113, 2009
-
(2009)
Cancer J
, vol.15
, pp. 110-113
-
-
Jimeno, A.1
Messersmith, W.A.2
Hirsch, F.R.3
|